Henderson-SmartDJ, De PaoliAG. Methylxanthine treatment for apnoea in preterm infants. Cochrane Database Syst Rev, 2010; 10:CD000140.
2.
LeeTC, CharlesB, SteerPet al.Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. Clin Pharmacol Ther, 1997; 61:628–640.
3.
CharlesBG, TownsendSR, SteerPAet al.Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring. Ther Drug Monit, 2008; 30:709–716.
4.
LeeTC, CharlesBG, SteerPAet al.Theophylline population pharmacokinetics from routine monitoring data in very premature infants with apnoea. Br J Clin Pharmacol, 1996; 41:191–200.
5.
SteerP, FlenadyV, ShearmanAet al.High dose caffeine citrate for extubation of preterm infants: a randomized controlled trial. Arch Dis Child Fetal Neonatal Ed, 2004; 89:499–503.
6.
GrayPH, FlenadyVJ, CharlesBGet al.Caffeine citrate for very preterm infants: effects on development, temperament and behaviour. J Paed Child Health, 2011; 47:167–172.
7.
SchmidtB, RobertsRS, DavisPet al.Caffeine for Apnea of Prematurity Trial Group: Caffeine therapy for apnea of prematurity. New Engl J Med, 2006; 354:2112–2121.
8.
SchmidtB, RobertsRS, DavisPet al.Caffeine for Apnea of Prematurity Trial Group: Long-term effects of caffeine therapy for apnea of prematurity. New Engl J Med, 2007; 357:1893–1902.
9.
DaniC, BertiniG, PezzatiMet al.Brain hemodynamic effects of doxapram in preterm infants. Biol Neonate, 2006; 89:69–74.
10.
CARE Study Group. Maternal caffeine intake during pregnancy and risk of fetal growth restriction: a large prospective observational study. Br Med J, 2008; 3:337–340.
11.
SchmidtB, AndersonPJ, DoyleLW. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA, 2012; 307:275–282.
12.
Di BlasiRM. Neonatal non-invasive ventilation techniques: do we really need to intubate?Respir Care, 2011; 56:1273–1294.
13.
SinkDW, HopeSA, HagadornJI. Nurse:patient ratio and achievement of oxygen saturation goals in premature infants. Arch Dis Child Fetal Neonatal Ed, 2011; 96:F93–98.
14.
ThomeUH, AmbalavananN. Permissive hypercapnia to decrease lung injury in ventilated preterm neonates. Semin Fetal Neonatal Med, 2009; 14:21–27.
15.
Henderson-SmartDJ, De PaoliAG. Prophylactic methylxanthine for prevention of apnoea in preterm infants. Cochrane Database Syst Rev, 2010; 812.CD 000432.
16.
PhilipRK, TheoCW, MirzaA, DunworthM. Caffeine treatment for apnoea of prematurity and mean daily weight gain: a prospective descriptive study in a defined birth cohort. Proceedings of International Pediatric Association (IPA) Meeting, Johannesburg, August 2010.
17.
PesceAJ, RashkinM, KotagalU. Standards of laboratory practice: theophylline and caffeine monitoring. Clin Chem, 1998; 44:1124–1128.
18.
ArandaJV, BeharryK, RexJet al.Caffeine enzyme immunoassay in neonatal and pediatric drug monitoring. Ther Drug Monit, 1987; 9:97–103.
19.
De WildtSN, KerkvlietKTM, WezenbergMGAet al.Use of saliva in therapeutic drug monitoring of caffeine in preterm infants. Ther Drug Monit, 2011; 23:250–254.
20.
NatarajanG, BoticaML, ThomasRet al.Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise?Pediatrics, 2007; 119:936–940.
21.
ZhaoJ, GonzalezF, MuD. Apnea of prematurity: from cause to treatment. Eur J Pediatr, 2011; 170:1097–1105.
22.
KumralA, TuzunF, YesilirmakDC, DumanN, OzkanH. Genetic basis of apnoea of prematurity and caffeine response: role of adenosine receptor polymorphisms: genetic basis of apnoea of prematurity. Acta Paediatr, 2012; 101:299–303.
23.
WilkinsonD, AndersenC, O'DonnellCP, De PaoliAG. High flow nasal cannula respiratory support in preterm infants. Cochrane Database Syst Rev, 2011; 1:CD006405.
